• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level and virulence of the 2009 pandemic influ

tetano

Editor, Senior Moderator
Antimicrob Agents Chemother. 2011 Dec 27. [Epub ahead of print]
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level and virulence of the 2009 pandemic influenza virus.
Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G.
Source

Research Center in Infectious Diseases of the CHUQ-CHUL and Laval University, Qu?bec City, Qu?bec, Canada.
Abstract

Amino acid substitutions at residue I223 of the neuraminidase (NA) protein have been identified in 2009 pandemic influenza (pH1N1) variants with altered susceptibilities to NA inhibitors (NAIs). We used reverse genetics and site-directed mutagenesis to generate the recombinant A/Qu?bec/144147/09 pH1N1 wild-type virus (WT) and five (I223R/V, H275Y, I223V- H275Y and I223R-H275Y) NA mutants. A fluorometric-based assay was used to determine IC(50) values against oseltamivir, zanamivir and peramivir. Replicative capacity was analyzed by viral yield assays in ST6GalI-MDCK cells. Infectivity and transmission of the WT, H275Y and I223V-H275Y recombinant viruses were evaluated in ferrets. As expected, the H275Y mutation conferred resistance to oseltamivir (982-fold) and peramivir (661-fold) compared to the drug-susceptible recombinant WT. The single I223R mutant was associated with reduced susceptibility to oseltamivir (53-fold), zanamivir (7-fold) and peramivir (10-fold) whereas the I223V virus had reduced susceptibility to oseltamivir (6-fold) only. Interestingly, enhanced levels of resistance to oseltamivir and peramivir and reduced susceptibility to zanamivir (1647-, 17347- and 16-fold increases in IC(50) values, respectively) were observed for the I223R-H275Y recombinant while the I223V-H275Y mutant exhibited 1733- 2707- and 2-fold increases in respective IC(50) values. The I223R/V changes were associated with equivalent or higher viral titers in vitro as compared to the recombinant WT. Infectivity and transmissibility in ferrets were comparable between the recombinant WT and the H275Y or I223V-H275Y recombinants. In conclusion, amino acid changes at residue I223 may alter the NAI susceptibilities of pH1N1 variants without compromising fitness. Consequently, I223R/V mutations, alone or with H275Y, need to be thoroughly monitored.

PMID:
22203589
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22203589
 
Back
Top Bottom